Table 4.

STROBE Statement—A checklist of items and the completeness of reporting score (COR %) for the included studies (n = 21).

	Item No.	Recommendation	Criteria Met (N, %) Yes No N/A
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	21(100)	0 (0)	0 (0)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	21 (100)	0 (0)	0 (0)
Introduction
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	21 (100)	0 (0)	0 (0)
Objectives	3	State-specific objectives, including any prespecified hypotheses	21 (100)	0 (0)	0 (0)
Methods
Study design	4	Present key elements of study design early in the paper	21 (100)	0 (0)	0 (0)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	21 (100)	0 (0)	0 (0)
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case–control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	N/A 3 (100) 16 (76.1)	N/A 0 (0) 2 (9.6)	N/A 0 (0) 3 (14.3)
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case–control study—For matched studies, give matching criteria and the number of controls per case	3 (100)	0 (0)	0 (0)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	19 (90.4)	2 (9.6)	0(0)
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	21 (100)	0 (0)	0 (0)
Bias	9	Describe any efforts to address potential sources of bias	19(90.4)	2 (9.6)	0 (0)
Study size	10	Explain how the study size was arrived at	20 (95.2)	1 (4.8)	0 (0)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	21 (100)	0 (0)	0 (0)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	20 (95.2)	1 (4.8)	0 (0)
		(b) Describe any methods used to examine subgroups and interactions	21 (100)	0 (0)	0 (0)
		(c) Explain how missing data were addressed	3 (14.3)	2 (9.6)	16 (76.1)
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case–control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	20 (95.2)	1 (4.8)	0 (0)
		( e ) Describe any sensitivity analyses	20 (95.2)	0 (0)	1 (4.8)
Results
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	21 (100)	0 (0)	0 (0)
		(b) Give reasons for non-participation at each stage	5 (23.8)	3 (14.3)	13 (61.9)
		(c) Consider use of a flow diagram	0 (0)	21 (100)	0 (0)
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	19 (90.4)	1 (4.8)	1 (4.8)
		(b) Indicate number of participants with missing data for each variable of interest	2 (9.6)	1 (4.8)	18 (85.6)
		(c) Cohort study—Summarize follow-up time (e.g., average and total amount)	N/A	N/A	N/A
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	N/A	N/A	N/A
		Case–control study—Report numbers in each exposure category, or summary measures of exposure	3(100)	0 (0)	18 (0)
		Cross-sectional study—Report numbers of outcome events or summary measures	19 (90.4)	2 (9.6)	0 (0)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	19 (90.4)	2 (9.6)	0 (0)
		(b) Report category boundaries when continuous variables were categorized	13 (61.9)	1 (4.8)	7 (33.3)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	13 (61.9)	5 (23.8)	3 (14.3)
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	21 (100)	0 (0)	0 (0)
Discussion
Key results	18	Summarize key results with reference to study objectives	21 (100)	0 (0)	0 (0)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11 (52.4)	10 (47.6)	0 (0)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15 (71.4)	6 (28.6)	0 (0)
Generalisability	21	Discuss the generalizability (external validity) of the study results	9 (42.9)	12 (57.1)	0 (0)
Other information
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13 (61.9)	7 (33.3)	1 (4.8)
Completeness of Reporting mean of the 21 studies (%)			87.0 ± 6.4%

"*" refer to Vandenbroucke et al., (71).